Table 2 Characteristics of male nAMD patients and male control subjects

Number of cases

24

26

17

9

–

–

Age (years)

73.8 ± 6.8

76.5 ± 7.0

77.9 ± 7.0

73.9 ± 6.7

0.162

0.166

nAMD type (typical:PCV:RAP)

–

10:15:1

8:8:1

2:7:0

–

0.352

Smoking (n, %)

15, 62.5

22, 84.6

15, 88.2

7, 77.8

0.082

0.482

HT (n, %)

15, 62.5

14, 53.8

11, 64.7

3, 33.3

0.545

0.141

DM (n, %)

0, 0.00

5, 19.2

4, 23.5

1, 11.1

0.022

0.445

d-ROMs (U. Carr)

363.4 ± 63.9

390.3 ± 64.5

384.1 ± 58.0

401.9 ± 77.7

0.146

0.557

BAP (μM/L)

2115.8 ± 226.5

2132.2 ± 317.4

2128.5 ± 228.7

2139.1 ± 458.3

0.833

0.949

SAF (AU)

2.0 ± 0.2

2.4 ± 0.4

2.3 ± 0.4

2.6 ± 0.2

< 0.001

0.017

Initial anti-VEGF drug (IVR:IVA)

–

7:19

4:13

3:6

–

0.592

Cases that switched drug (n, %)

–

9, 34.6

5, 29.4

4, 44.4

–

0.443

Number of IVIs (one year)

–

5.5 ± 1.6

4.7 ± 1.5

7.0 ± 0.0

–

 < 0.001

VA (logMAR)

 Pre-teatment

–

0.32 ± 0.38

0.28 ± 0.28

0.39 ± 0.54

–

0.573

 One month later

–

0.34 ± 0.45

0.26 ± 0.31

0.49 ± 0.63

–

0.345

 One year later

–

0.28 ± 0.40

0.26 ± 0.39

0.31 ± 0.46

–

0.786

CMT (μm)

 Pre-treatment

–

320.1 ± 66.6

308.4 ± 64.5

342.1 ± 72.7

–

0.261

 One month later

–

243.3 ± 52.3

247.2 ± 48.6

236.4 ± 63.6

–

0.667

 One year later

–

239.2 ± 76.7

241.6 ± 72.1

234.9 ± 92.7

–

0.854